Baxter Recalls One Lot of Nitroglycerin in 5% Dextrose Injection

News
Article

Baxter has issued a voluntary recall of one lot of nitroglycerin in 5% dextrose injection after particulate matter was found in one vial.

Baxter has issued a voluntary recall of one lot of nitroglycerin in 5% dextrose injection after particulate matter was found in one vial. This recall is being conducted with the knowledge of the US FDA.

Injection of particulate matter can lead to blockage of blood vessels. It can also cause inflammation, particularly in the lungs, and local irritation of blood vessels due to the presence of foreign material. No adverse events associated with this issue have been reported to date.

Baxter's nitroglycerin in 5% dextrose injection is packaged in 250 mL glass containers, with 12 glass containers per carton. The affected product code is 1A0694, and the affected lot number is G105197. Products affected by this recall were distributed in Colombia, Saudi Arabia and the United States between January 17, 2013, and October 10, 2013. Baxter has notified its customers not to use product from the recalled lot and to return all affected product.

Source: Baxter

Recent Videos
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.